Next-Generation Phosphorothioate-conjugated miRNAs for Personalized Medicine
Legal Citation
Summary of the Inventive Concept
A novel, next-generation technology for treating multiple myeloma and other diseases using phosphorothioate-conjugated miRNAs, incorporating advanced delivery systems, personalized medicine approaches, and real-time monitoring capabilities.
Background and Problem Solved
The original patent disclosed phosphorothioate-conjugated miRNAs for treating multiple myeloma, but it had limitations in terms of delivery, efficacy, and patient specificity. The new inventive concept addresses these limitations by introducing nanoparticle-based delivery, personalized medicine approaches, and real-time monitoring capabilities, enabling more effective and targeted treatment of diseases.
Detailed Description of the Inventive Concept
The next-generation technology comprises a nucleic acid conjugate with a microRNA selected from the group consisting of let7a-3p miRNA, let7a-5p miRNA, miR17-3p miRNA, miR17-5p miRNA, and miR218-5p miRNA. The conjugate is delivered via a nanoparticle with a tunable release profile, allowing for controlled and sustained release of the microRNA. Additionally, the technology incorporates a device for monitoring treatment efficacy and a bioinformatics tool for predicting treatment outcomes, enabling personalized medicine approaches. The system also includes a composition of matter comprising a nucleic acid conjugate with a microRNA and a polymer matrix with tunable biodegradability, which is implantable and releases the conjugate in a controlled manner.
Novelty and Inventive Step
The new claims introduce several novel and non-obvious features, including nanoparticle-based delivery, personalized medicine approaches, and real-time monitoring capabilities, which are not present in the original patent. The combination of these features enables a more effective and targeted treatment of diseases, which is not obvious from the original patent.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include different types of nanoparticles, such as liposomes or dendrimers, or different polymer matrices with varying biodegradability profiles. Additionally, the technology could be adapted for use with different microRNAs or nucleic acid conjugates, or for treating different diseases.
Potential Commercial Applications and Market
The next-generation technology has significant commercial potential in the treatment of multiple myeloma and other diseases, particularly in the context of personalized medicine. The technology could be licensed to pharmaceutical companies or used to develop new products and services in the healthcare industry.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K47/549 |
| A | A61 | A61K47/548 |
| A | A61 | A61K48/00 |
| C | C12 | C12N15/113 |
| C | C12 | C12N2310/141 |
| C | C12 | C12N2320/30 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Molecular Biology and Pharmaceutical Biotechnology, focusing on microRNA delivery systems, nucleic acid conjugation, and personalized medicine technologies with expertise in nanoparticle drug delivery and genetic therapeutic interventions
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in molecular biology or pharmaceutical sciences, experienced in microRNA manipulation, drug delivery system design, and understanding of conjugation techniques for therapeutic nucleic acids
Obviousness Rationale
A person of ordinary skill would recognize that the PTD's disclosed variations represent predictable extensions of the source patent's foundational microRNA conjugation technology. The nanoparticle delivery, personalized medicine approaches, and monitoring systems are logical technological progressions that would be apparent to a skilled researcher seeking to improve therapeutic efficacy and patient-specific treatment strategies. The core microRNA selection remains consistent with the source patent, while the additional technological layers represent incremental yet obvious innovations in the field.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,633 |
|---|---|
| Title | Phosphorothioate-conjugated miRNAs and methods of using the same |
| Assignee(s) | City of Hope |